We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.

4th Department of Internal Medicine Hematology University Hospital Hradec Kralove and Charles University Prague Faculty of Medicine in Hradec Kralove Czech Republic Hradec Kralove Czech Republic

Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA

Division of Hematology Mayo Clinic Rochester MN USA

Zobrazit více v PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. PubMed DOI

Kumar SK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520. doi: 10.1182/blood-2007-10-116129. PubMed DOI PMC

Kumar SK, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128. doi: 10.1038/leu.2013.313. PubMed DOI PMC

Greipp PR, et al. International staging system for multiple myeloma. J. Clin. Oncol. 2005;23:3412–3420. doi: 10.1200/JCO.2005.04.242. PubMed DOI

Mikhael JR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 2013;88:360–376. doi: 10.1016/j.mayocp.2013.01.019. PubMed DOI

Palumbo A, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J. Clin. Oncol. 2015;33:2863–2869. doi: 10.1200/JCO.2015.61.2267. PubMed DOI PMC

Konigsberg R, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J. Clin. Oncol. 2000;18:804–812. doi: 10.1200/JCO.2000.18.4.804. PubMed DOI

Fonseca R, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–4575. doi: 10.1182/blood-2002-10-3017. PubMed DOI

Avet-Loiseau H, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489–3495. doi: 10.1182/blood-2006-08-040410. PubMed DOI

Kumar SK, et al. Multiple myeloma. Nat. Rev. Dis. Prim. 2017;3:17046. doi: 10.1038/nrdp.2017.46. PubMed DOI

Avet-Loiseau H, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J. Clin. Oncol. 2012;30:1949–1952. doi: 10.1200/JCO.2011.36.5726. PubMed DOI

Avet-Loiseau H, et al. P53 deletion is not a frequent event in multiple myeloma. Br. J. Haematol. 1999;106:717–719. doi: 10.1046/j.1365-2141.1999.01615.x. PubMed DOI

Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105:358–360. doi: 10.1182/blood-2004-04-1363. PubMed DOI

Testoni N, et al. High-risk cytogenetics in newly diagnosed multiple myeloma: prognostic relevance of co-segregations and analysis of the role of double versus single autotransplantation. Blood. 2017;130(Suppl 1):394.

Thanendrarajan S, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017;102:e364–e367. doi: 10.3324/haematol.2017.168872. PubMed DOI PMC

Niklas Z, et al. Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance. Br. J. Haematol. 2002;117:852–859. doi: 10.1046/j.1365-2141.2002.03529.x. PubMed DOI

Chang H, Yeung J, Qi C, Xu W. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. Br. J. Haematol. 2007;138:324–329. doi: 10.1111/j.1365-2141.2007.06649.x. PubMed DOI

Kumar S, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100–2105. doi: 10.1182/blood-2011-11-390658. PubMed DOI PMC

Ortega MM, et al. A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma. Ann. Hematol. 2003;82:405–409. doi: 10.1007/s00277-003-0632-2. PubMed DOI

Xiong W, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112:4235–4246. doi: 10.1182/blood-2007-10-119123. PubMed DOI PMC

Schultheis B, et al. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia. 1999;13:2099–2103. doi: 10.1038/sj.leu.2401609. PubMed DOI

Tiedemann RE, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044. doi: 10.1038/leu.2008.4. PubMed DOI PMC

Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br. J. Haematol. 2004;127:280–284. doi: 10.1111/j.1365-2141.2004.05199.x. PubMed DOI

Drach J, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–809. PubMed

Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105:358–360. doi: 10.1182/blood-2004-04-1363. PubMed DOI

Chng WJ, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006;20:807. doi: 10.1038/sj.leu.2404172. PubMed DOI

Boyd KD, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26:349–355. doi: 10.1038/leu.2011.204. PubMed DOI PMC

Pawlyn C, et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015;125:831–840. doi: 10.1182/blood-2014-07-584268. PubMed DOI PMC

Hebraud B, et al. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood. 2015;125:2095–2100. doi: 10.1182/blood-2014-07-587964. PubMed DOI PMC

Merz M, et al. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Am. J. Hematol. 2016;91:E473–e7. doi: 10.1002/ajh.24533. PubMed DOI

Shah V, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2017;32:102. doi: 10.1038/leu.2017.179. PubMed DOI PMC

Teoh PJ, et al. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia. 2014;28:2066–2074. doi: 10.1038/leu.2014.102. PubMed DOI

Herrero AB, Rojas EA, Misiewicz-Krzeminska I, Krzeminski P, Gutiérrez NC. Molecular mechanisms of p53 deregulation in cancer: an overview in multiple myeloma. Int. J. Mol. Sci. 2016;17:2003. doi: 10.3390/ijms17122003. PubMed DOI PMC

Chng WJ, et al. Clinical significance of TP53 mutation in myeloma. Leukemia. 2007;21:582–584. doi: 10.1038/sj.leu.2404524. PubMed DOI

Walker BA, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol. 2015;33:3911–3920. doi: 10.1200/JCO.2014.59.1503. PubMed DOI PMC

Lodé L, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95:1973–1976. doi: 10.3324/haematol.2010.023697. PubMed DOI PMC

Boyd KD, et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes, Chromosomes & Cancer. 2011;50:765–774. doi: 10.1002/gcc.20899. PubMed DOI

Kortüm KM, et al. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3)P) in -17p high risk disease. Br. J. Haematol. 2015;168:507–510. doi: 10.1111/bjh.13171. PubMed DOI PMC

Chin M, et al. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Blood Cancer J. 2017;7:e610. doi: 10.1038/bcj.2017.76. PubMed DOI PMC

Shah V, et al. Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients. Blood. 2017;130(Suppl 1):4331.

Binder M, et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J. 2016;6:e401. doi: 10.1038/bcj.2016.15. PubMed DOI PMC

Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548. doi: 10.1016/S1470-2045(14)70442-5. PubMed DOI

International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol.121, 749–757 (2003). PubMed

Greipp PR, Kumar S. Plasma cell labeling index. Methods Mol. Med. 2005;113:25–35. PubMed

Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346. doi: 10.1016/S1470-2045(16)30206-6. PubMed DOI

Rajkumar SV, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–4695. doi: 10.1182/blood-2010-10-299487. PubMed DOI PMC

Avet-Loiseau H, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p) J. Clin. Oncol. 2010;28:4630–4634. doi: 10.1200/JCO.2010.28.3945. PubMed DOI

Sonneveld P, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J. Clin. Oncol. 2012;30:2946–2955. doi: 10.1200/JCO.2011.39.6820. PubMed DOI

Neben K, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119:940–948. doi: 10.1182/blood-2011-09-379164. PubMed DOI

Rajkumar SV, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27:1738–1744. doi: 10.1038/leu.2013.86. PubMed DOI PMC

Neben K, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J. Clin. Oncol. 2013;31:4325–4332. doi: 10.1200/JCO.2012.48.4923. PubMed DOI

Lakshman A., et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 32, 1811–1815 (2018). PubMed

An G, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin. Cancer Res. 2015;21:2148–2156. doi: 10.1158/1078-0432.CCR-14-2576. PubMed DOI

Jakubowiak AJ, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801–1809. doi: 10.1182/blood-2012-04-422683. PubMed DOI PMC

Munshi NC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28–35. doi: 10.1001/jamaoncol.2016.3160. PubMed DOI PMC

Impact of acquired del(17p) in multiple myeloma